HealthDay News — New antibiotic therapy, especially inpatient treatment, is associated with greater likelihood of recovery after acute lung function decline in children with cystic fibrosis, according to a study published in the Annals of the American Thoracic Society.
Wayne J. Morgan, MD, from the University of Arizona in Tucson, and colleagues used data from the Epidemiologic Study of Cystic Fibrosis to identify episodes of forced expiratory volume in one second (FEV1) decline (≥10% from baseline; 9,875 patients) and determine if antibiotic treatment was associated with recovery to baseline, or near baseline.
The researchers found that new antibiotic treatment was associated with an increased likelihood of recovery to 90% of baseline (P<.001), especially for hospitalization compared to no new antibiotic (odds ratio, 2.79). All 4 outpatient treatments (home intravenous antibiotic, inhaled antibiotic, oral quinolone antibiotic, or other oral antibiotic) were associated with greater likelihood of recovery compared to no treatment (odds ratios, 1.27 to 1.64); however, inpatient treatment was better than outpatient treatments (odds ratio, 1.94).
“Benefits extend across all disease stages and are especially important in patients with high lung function, who are at greatest risk for FEV1 decline,” the researchers write.
Several authors report financial ties to Genentech, which funded the study.
Morgan WJ, Wagener JS, Pasta DJ, Millar SJ, VanDevanter DR, Konstan MW, Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Relationship of antibiotic treatment to recovery after acute FEV1 decline in children with cystic fibrosis [published online March 21, 2017]. Ann Am Thorac Soc. doi: 10.1513/AnnalsATS.201608-615OC
This article originally appeared on Infectious Disease Advisor